Design Therapeutics (DSGN) vs Faeth Therapeutics (FTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed Design Therapeutics (DSGN) over the past year, gaining 123.1% versus a gain of 80.1%. Over five years, DSGN leads with a -18.0% price change compared with -83.2% for FTH. Design Therapeutics is the larger company by market cap ($719.1 million vs $661.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DSGN | FTH |
|---|---|---|
| Share price | $11.49 | $25.61 |
| Market cap | $719.06M | $661.77M |
| 1-day change | -1.71% | +2.77% |
| YTD return | +24.63% | +140.02% |
| 1-year return | +80.12% | +123.08% |
| 5-year return | -17.96% | -83.22% |
| EPS (TTM) | $-1.18 | $-60.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $42.14 |
| 52-week low | $5.28 | $7.45 |
| Distance from 52-week high | -33.39% | -39.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.95% | +121.28% |
| Average volume | 603.58K | 351.88K |
| Shares outstanding | 62.58M | 25.84M |
| Employees | 55 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed DSGN by 43.0 percentage points over the past year.
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
DSGN vs FTH FAQ
Which is bigger, Design Therapeutics or Faeth Therapeutics?
Design Therapeutics (DSGN) is larger, with a market capitalization of $719.06M compared with $661.77M for Faeth Therapeutics (FTH).
Which stock has performed better over the past year, DSGN or FTH?
FTH returned +123.08% over the past 12 months, compared with +80.12% for DSGN (price return, excluding dividends). Past performance does not predict future results.
Are Design Therapeutics and Faeth Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.